Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

107 results about "DNA-binding protein" patented technology

DNA-binding proteins are proteins that have DNA-binding domains and thus have a specific or general affinity for single- or double-stranded DNA. Sequence-specific DNA-binding proteins generally interact with the major groove of B-DNA, because it exposes more functional groups that identify a base pair. However, there are some known minor groove DNA-binding ligands such as netropsin, distamycin, Hoechst 33258, pentamidine, DAPI and others.

Methods and compositions for editing nucleotide sequences

The present disclosure provides new prime editor guide RNAs for prime editing, constructs for prime editing, and methods for using same. In addition, the present disclosure provides compositions and methods for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis (e.g., insertion or deletion). The nucleotide change can include a single-nucleotide change (e.g., any transition or any transversion), an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a prime editor RNA (PEgRNA). The prime editor guide RNA comprises an extension arm that provides a DNA synthesis template sequence which encodes a single strand DNA flap, which is homologous to an endogenous DNA sequence, but which contains the desired one or more nucleotide changes and which, following synthesis by the polymerase (e.g., reverse transcriptase), becomes incorporated into the target DNA molecule.
Owner:HOWARD HUGHES MEDICAL INST +2

DNA binding protein and RNA binding protein classification method based on ESM-2 and dual-path neural network

ActiveCN119229982Aproportional balancequality improvementBiostatisticsBiological modelsA-DNANucleic acid binding protein
The invention provides a DNA binding protein and RNA binding protein classification method based on ESM-2 and a dual-path neural network, and particularly relates to a staged classification method combining the ESM-2 and the dual-path neural network, which is called DRBP-EDP. In the first stage training, the protein sequence is classified as a nucleic acid binding protein or a non-nucleic acid binding protein; further classifying the nucleic acid binding protein as a DNA binding protein or an RNA binding protein in the second stage of training; meanwhile, a fine data set construction method is further constructed, so that a high-quality protein classification data set is created, through the method, the DRBP-EDP model obtains good performance, the classification accuracy of the nucleic acid binding protein and the non-nucleic acid binding protein in the first stage is 90.03%, and the classification accuracy of the non-nucleic acid binding protein in the second stage is 90.03%. In the second stage, the classification accuracy of the DNA binding protein and the RNA binding protein is 89.56%, a new insight and a new method are provided for protein classification, an innovative tool is provided for research on protein functions, and therefore a new opportunity is provided for development of life science.
Owner:SANYA NATIONAL INSTITUTE OF SOUTHERN BREEDING CHINESE ACADEMY OF AGRICULTURAL SCIENCES +1

Base editors and uses thereof

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. The disclosure provides fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cas9 or variants thereof, and nucleic acid editing proteins such as cytidine deaminase domains (e.g., novel cytidine deaminases generated by ancestral sequence reconstruction), and adenosine deaminases that deaminate adenine in DNA. Aspects of the disclosure relate to fusion proteins (e.g., base editors) that have improved expression and / or localize efficiently to the nucleus. In some embodiments, base editors are codon optimized for expression in mammalian cells. In some embodiments, base editors include multiple nuclear localization sequences (e.g., bipartite NLSs), e.g., at least two NLSs. In some embodiments, methods for targeted nucleic acid editing are provided.
Owner:THE BROAD INST INC

Methods and compositions for prime editing nucleotide sequences

Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.
Owner:THE BROAD INST INC

Recruitment of DNA polymerase for templated editing

This invention relates to recombinant nucleic constructs comprising a sequence-specific DNA binding protein, DNA-dependent DNA polymerase and a DNA encoded repair template, optionally a DNA endonuclease or wherein the sequence-specific DNA binding protein comprises DNA endonuclease activity, and methods of use thereof for modifying nucleic acids in cells and organisms.
Owner:PAIRWISE PLANTS SERVICES INC

Humanized Anti-TDP-43 Binding Molecules and Uses Thereof

The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to humanized TDP-43 specific binding molecules, in particular to humanized anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and / or treat a disease, disorder and / or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Owner:AC IMMUNE SA

Using programmable DNA binding proteins to enhance targeted genome modification

Compositions and methods for using programmable DNA binding proteins to increase the efficiency and / or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.
Owner:EMD MILLIPORE CORP

Application of DNA binding protein Mse7 in removal of host nucleic acid in recombinant protein

The invention discloses application of DNA (deoxyribonucleic acid) binding protein Mse7 in removal of host nucleic acid in recombinant protein, a chromatography medium based on the DNA binding protein Mse7 comprises biotin ligase, streptavidin agarose gel and the DNA binding protein Mse7, and the DNA binding protein Mse7 is connected with an Avi-tag label. The method comprises the following steps: co-expressing biotin ligase and DNA (Deoxyribose Nucleic Acid) binding protein in vivo to obtain biotinylated Mse7 protein; purifying and concentrating; and finally, incubating and combining the Mse7 with streptavidin agarose gel to form a new chromatographic filler. The DNA binding protein Mse7 serves as a novel chromatography medium to be applied to removal of host nucleic acid in recombinant protein, host DNA can be effectively removed, the purity of a product is improved, and compared with a traditional method, the technology has higher purification efficiency and recovery rate.
Owner:JIANGSU OCEAN UNIV +1

Methods and compositions for prime editing nucleotide sequences

Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.
Owner:THE BROAD INST INC

High-flux rapid chromatin immunoprecipitation sequencing method based on HiBiT tag and Tn5 enzyme

The invention discloses a high-flux and rapid chromatin immunoprecipitation sequencing method based on a HiBiT tag and a Tn5 enzyme, and belongs to the technical field of biology. According to the method, the high affinity characteristic of a HiBiT tag system is combined with a Tn5 enzyme in-situ library building technology, firstly, a DNA binding protein recombinant expression strain containing a HiBiT tag is constructed and subjected to induced expression, after formaldehyde crosslinking and cell lysis, an Anti-HiBiT antibody is used for rapid immunoprecipitation, and a Tn5 enzyme library is constructed; tn5 transposase is directly loaded on the magnetic beads combined with the protein and DNA fragment compound to complete fragmentation and linker connection, so that the construction of a next-generation sequencing library is quickly carried out, and the total consumed time from immunoprecipitation to the completion of library construction is less than or equal to 5 hours. Meanwhile, automatic treatment is realized through a micro experiment board (the reaction system is less than or equal to 200 microliters) and a liquid workstation, the experiment cost and the sample dosage are reduced, 48 transcription factors and 48 control samples can be synchronously treated, the efficiency is greatly improved, and an efficient tool is provided for microbial transcription regulation and control research.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Filler for removing host nucleic acid residues in biological tool enzyme through DNA binding protein Ssh7b and application of filler

The invention discloses a method for removing host nucleic acid residues in a biological tool enzyme by DNA (deoxyribonucleic acid) binding protein Ssh7b, which comprises the following steps: co-expressing biotin ligase and DNA binding protein in vivo to obtain biotinylated Ssh7b protein; purifying and concentrating; and finally, incubating and combining the Ssh7b and streptavidin agarose gel to form a new chromatographic filler, enabling the sample solution to flow through the newly prepared chromatographic filler, and collecting the flow-through solution, thereby achieving the purpose of removing the host DNA. According to the method disclosed by the invention, the purpose of removing the host DNA is achieved by utilizing a mode of coupling the DNA binding protein Ssh7b and the streptavidin, so that the double-stranded DNA residual quantity in the biological tool enzyme is further reduced, and the product quality of the biological tool enzyme is improved.
Owner:JIANGSU OCEAN UNIV +1

Compositions and methods for treating TDP-43 proteinopathy

The present disclosure relates to the use of UNC13A cryptic exon splice variant specific inhibitors for methods of reducing expression of a UNC13A cryptic exon splice variant in a cell, reducing phosphorylated TAR-DNA binding protein-43 (TDP-43) in a cell, treating TAR-DNA binding protein-43 (TDP-43) proteinopathy in a subject, or treating a subject has been identified as having a UNC13A mutation in intron 20-21 of UNC13A. Antisense oligonucleotides directed against UNC13A cryptic splice variant are also contemplated.
Owner:TRACE NEUROSCIENCE INC

Protease-conditional targeted nucleic acid recombination, method and uses thereof

The present disclosure relates to enzymes, compositions and methods for performing conditional homologous recombination of a targeted DNA molecule or genome by using modified proteins comprising nucleic acid DNA binding proteins with protease-conditional recombinase (hereinafter “ProRec”) activity. Namely a new cre recombinase pro enzyme, compositions / kit and sensors comprising the cre recombinase pro enzyme of the present disclosure. Namely, a cre recombinase pro-enzyme, for identifying and quantifying proteolytic activity in a disease or an infection, comprising intein mediated circularization, a flip-excision cassette comprising an output reporter and / or effector protein; a linker sequence cleavable by a protease.
Owner:INST OF EXPERIMENTAL & TECH BIOLOGY IBET

Leader editor capable of improving editing activity, gene editing system comprising leader editor and application of leader editor

The invention provides a leader editor capable of improving editing activity, a gene editing system comprising the leader editor and application of the leader editor. Specifically, the present disclosure provides a leader editor wherein the leader editor comprises a nucleic acid programmable DNA binding protein (napDNAbp), a reverse transcriptase, and a single stranded DNA annealing protein (SSAP). In the constructed pilot editor or gene editing system, different SSAPs are fused with a PE2 system which does not cause DNA double-chain breakage (PE2-SSAPs), so that the editing efficiency of the PE2 system is improved, and meanwhile, high accuracy is kept.
Owner:INNOVEC BIOTHERAPEUTICS

Method for inducing pichia pastoris to express human alpha-lactalbumin by using ethanol

PendingCN119685181AFungiMicroorganism based processesSignal recognition particleHeterologous
The invention relates to a method for inducing pichia pastoris to express human alpha-lactalbumin by using ethanol, and belongs to the technical field of genetic engineering. Recombinant pichia pastoris using ethanol as an inducer for heterologous expression of human alpha-lactalbumin is constructed, three different expression vectors are used in the construction process, the first expression vector uses an ethanol inducible promoter to express fusion polypeptide of DNA binding protein and a transcription activator, and the second expression vector uses an ethanol inducible promoter to express fusion polypeptide of human alpha-lactalbumin. The second expression vector sequentially expresses a protein binding sequence, a methanol inducible promoter, an alpha signal peptide and human alpha-lactalbumin, the third expression vector overexpresses a signal recognition particle subunit participating in a protein targeting endoplasmic reticulum, and the yield of the constructed recombinant pichia pastoris shake flask fermentation human alpha-lactalbumin is 23.3 mg / L; the yield of the human alpha-lactalbumin reaches 1.1 g / L in a 3L fermentation tank, and methanol is not required to be added as an inducer in the fermentation process, so that the problems of toxicity and safety possibly caused by methanol are avoided, and efficient production of the human alpha-lactalbumin is realized.
Owner:JIANGNAN UNIV

Engineered DNA binding proteins

Provided herein are compositions comprising a non-naturally occurring DNA binding protein that modulates expression of an endogenous gene. Provided herein are methods of use thereof of the compositions which comprise a non-naturally occurring DNA binding protein that modulates expression of an endogenous gene.
Owner:ENCODED THERAPEUTICS INC

Method of modulating VEGF and uses thereof

The invention provides for a composition, which in particular comprising a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, wherein the fusion molecule is targeted to a genomic region near a VEGF gene and / or within a VEGF regulatory element and the at least one modulator of gene expression provides a modification of at least one nucleotide near the VEGF gene and / or within a VEGF regulatory element. The invention also provides methods of reduction or elimination of VEGF gene products in vivo and uses thereof.
Owner:EPIGENIC THERAPEUTICS PTE LTD

In-vivo base editing system for magnetic navigation

The invention relates to the technical field of medical imaging, in particular to a magnetic navigation in-vivo basic group editing system, which comprises a magnetic navigation module, a magnetic navigation module, an in-vivo basic group editing module and an in-vivo basic group editing module, and is characterized in that the magnetic navigation module is used for providing a magnetic navigation electromagnetic selection field and a magnetic navigation electromagnetic excitation field; the receiving signal acquisition module is arranged on the magnetic navigation module and is used for receiving the magnetic induction signal of the experimental object in the magnetic navigation module; the in-vivo gene editing module adopts pcDNA3.1 as a plasmid vector, DNA binding protein Cas9 and cytidine deaminase or IS621mRNA as a base editor, and the base editor is used for realizing gene expression and comprises a dTtomato sequence, an EPG sequence and an hAPOBE3A sequence; and the control module is used for controlling the magnetic navigation module and the received signal acquisition module through an FPGA (Field Programmable Gate Array) board and a PC (Personal Computer) terminal.
Owner:BEIHANG UNIV

Compositions and methods for altering complement activation

Compositions and methods for reducing complement activation by introducing one or more alterations into a complement factor B (CFB) polynucleotide in a cell. In particular embodiments, the invention of the disclosure features a base editor system (e.g., a fusion protein or complex comprising a programmable DNA binding protein, a nucleobase editor, and gRNA) for modifying a CFB polynucleotide, where the modification is associated with reduced expression, and / or reduced activity of the CFB polypeptide encoded by the polynucleotide.
Owner:BEAM THERAPEUTICS INC +4

HAPP gene and application thereof

The invention discloses an HAPP gene and application thereof, and relates to the field of plant genetic engineering, the identified rice HAPP gene can increase the rice plant height and the seed size at the same time, and after the rice HAPP gene is fused with a PANDA gene, the rice plant height and the seed size can be remarkably increased, but the ear number is reduced. Meanwhile, analysis finds that HAPP originates from a Harbinger transposon Myb-like DNA binding protein, interacts with PANDA and is related to a gene expression mode, but has antagonism in function. Therefore, identification of the HAPP gene not only reveals a new function of the transposon-derived gene in regulation and control of rice yield traits, but also provides new theoretical support and practical guidance for rice breeding.
Owner:INSTITUTE OF SUBTROPICAL AGRICULTURE CHINESE ACADEMY OF SCIENCES +2

Methods and compositions for prime editing nucleotide sequences

Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.
Owner:THE BROAD INST INC

Compositions and methods for treating tardbp associated diseases

The present invention relates to the field of antisense oligonucleotides used to reduce expression of the transactive response DNA binding protein 43 (TARDBP) gene which encodes the protein TAR DNA-binding protein 43 (TDP43). The present invention also relates to the field of antisense oligonucleotides used to prevent the subsequent downregulation of stathmin-2. The invention also provides pharmaceutical compositions and methods to treat the effects of a disease associated with TDP43 proteinopathy by administration of antisense oligonucleotides and therapeutic compositions comprising AONs targeted to TARDBP and AONs targeted to STMN2.
Owner:PERRON INST FOR NEUROLOGICAL & TRANSLATIONAL SCI LTD

Chromatin analysis compositions and methods

Compositions and methods for single reaction and multiplex analysis of histone modification. Compositions include a binding domain and a linker or a nucleosome binding conjugate comprising a binding domain bound to the linker. The method comprises analyzing a plurality of nucleosomes, comprising: (i) contacting a plurality of matrices comprising a binding domain and a linker composition with a solution comprising a plurality of nucleosomes wherein nucleosomes comprising a histone modification or DNA binding protein are bound to the binding domain; (ii) attaching a linker carrying a nucleic acid barcode to a target DNA of a nucleosome comprising a histone modification or DNA binding protein; (iii) introducing a universal sequence for amplifying the target DNA; (iv) amplifying the barcode labeled target DNA; and (v) analyzing the amplified barcode-labeled target DNA by sequencing.
Owner:ALIDA BIOSCIENCES INC

Novel compounds for the diagnosis of TDP-43 proteinopathies

The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Owner:AC IMMUNE SA

Methods for detecting chromatin accessibility or DNA-binding protein footprints in cells based on a two-enzyme approach

The present invention belongs to the field of biotechnology. In particular, the present invention relates to a method for detecting chromatin accessibility or DNA binding protein footprint in cells based on a two-enzyme method. More specifically, the present invention relates to a method for converting information on the openness of chromatin into information on mutations in DNA sequences by means of adenine methyltransferase and adenine deaminase, thereby quantitatively determining the chromatin accessibility of DNA molecules and the binding footprint of DNA binding proteins, such as transcription factors.
Owner:SHANGHAI TONGJI HOSPITAL +1

Mapping DNA binding

Provided herein are techniques relating to the identification of binding sites of DNA binding proteins, and in particular, but not exclusively, to methods, systems and kits for simultaneous mapping of binding sites of multiple proteins in the same cell using affinity reagent specific barcodes.
Owner:JOHNS HOPKINS UNIVERSITY +1